PSTX Profile
Poseida Therapeutics Inc (PSTX) is a clinical-stage biopharmaceutical company that develops and commercializes genetically engineered cell therapies for the treatment of cancer and other genetic diseases. The company's proprietary technology platform, called the PiggyBac DNA Modification System, is designed to overcome some of the limitations of current gene therapy approaches by enabling efficient and precise delivery of therapeutic genes into the genome of target cells.
Poseida's lead product candidate, P-BCMA-101, is a CAR-T therapy for the treatment of relapsed/refractory multiple myeloma (RRMM). P-BCMA-101 is currently being evaluated in a Phase 1 clinical trial, with preliminary data showing promising safety and efficacy results. The company also has a pipeline of other CAR-T and gene therapies for the treatment of solid tumors and genetic diseases, including liver-directed gene therapy for hemophilia B.
Poseida was founded in 2015 and is headquartered in San Diego, California. The company is backed by several venture capital firms and has partnerships with several pharmaceutical companies, including Janssen Biotech and Takeda Pharmaceuticals.
|
